Pasahan, RamazanDemirci, OzlemTaskin, Irmak IcenPasahan, AzizSever, Meryem RuveydaGok, YetkinAktas, Aydin2026-04-042026-04-0420251573-40641875-6638https://doi.org/10.2174/0115734064331622241113032042https://hdl.handle.net/11616/108804Background This work presents the synthesis of Ru(II)NHC complexes bearing a series of 4-fluorobenzyl group. These complexes have been characterized by a variety of spectroscopic methods (1H NMR, 13C NMR, and FTIR) and by elemental analysis techniques.Methods These complexes' antitumor activities against SH-SY5Y (human neuroblastoma) and HCT116 (human colon cancer) were investigated by 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT) assay.Results The results showed that all the synthesized complexes exhibited significant cytotoxic effect with low IC50 values 15 +/- 0.57, 15.26 +/- 0.71, 7.64 +/- 0.30, 27.66 +/- 0.36 and 14.45 +/- 0.84 (mu g/mL) respectively.Conclusion Furthermore, apoptosis assessed by double labeling with Annexin V-FITC/PI indicated that complexes 1b and 1d can effectively induce apoptosis and inhibit cell proliferation at the S phase in SH-SY5Y cells. Taken together, Ru(II)NHC complexes containing the 4-fluorobenzyl group have significant potential for the development of novel, highly effective anticancer agents.eninfo:eu-repo/semantics/closedAccessAntitumor activitybenzimidazoleDNA bindingN-heterocyclic carbenesorganometallicrutheniumArticle2165465533995045510.2174/01157340643316222411130320422-s2.0-105013020916Q3WOS:001548464300010Q30000-0001-8496-67820000-0002-0657-38840000-0002-3221-14220000-0001-9271-1528